This corroborates our previous findings showing that HER2-TAC T cells outperformed CD28-based HER2-CAR T cells in a solid tumor mouse model with increased antitumor efficacy, reduced toxicity, and faster tumor infiltration (1). This evidence concerns the gene CD28 and neoplasm.